RESOURCES
News
Cancer Today Spotlights Lynx Dx’s MPS2 as a Breakthrough At-Home Prostate Cancer Test
In a recent feature, Cancer Today explores how MyProstateScore 2.0 (MPS2) may help men avoid unnecessary or [...]
Lynx Dx Launches Ordering for At-Home Collection Version of MyProstateScore 2.0
MyProstateScore 2.0 (MPS2) will be made available for at-home sample collection.
Lynx Dx Introduces At-Home Collection Option for MyProstateScore 2.0
MyProstateScore 2.0 (MPS2) will be made available for at-home sample collection.
Lynx Dx Announces Medicare Coverage for MyProstateScore 2.0, Marking a Major Milestone in Prostate Cancer Risk Assessment
Lynx Dx is proud to announce that MyProstateScore 2.0 (MPS2) has been approved for coverage from Medicare.
Lynx Dx Wins Award as One of ’50 Companies to Watch’ by Michigan Celebrates Small Business
ANN ARBOR, Mich.– Lynx Dx, a leader in innovative diagnostic solutions, has been recognized as one [...]
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Lynx Dx's Biomarker Test Offers Market-Leading Accuracy in Prostate Cancer Risk Assessment ANN ARBOR, Mich., April [...]
Lynx Dx Relocates to New and Improved Headquarters to Prime Next Phase of Growth
ANN ARBOR, MI – Lynx Dx, an Ann Arbor-based genomics startup and developer of the revolutionary MyProstateScore [...]
Lynx Dx, Inc.’s Laboratory Receives Accreditation from the College of American Pathologists
ANN ARBOR, MI – The Accreditation Committee of the College of American Pathologists (CAP) awarded accreditation to [...]
Lynx Dx, Inc. Website Wins Gold in 25th Anniversary Digital Health Awards®
ANN ARBOR, MI – Lynx Dx,Inc. was selected as a winner in the 25th anniversary Digital [...]